重组Anti-PD-L1抗体[28-8]

FURTHER INFORMATION ON POSITIVE CONTROLS (Chinese version)

Tissue:
- Tonsil - with hyperreactive changes. Screening of hyper-reactive tonsils is recommended to find tonsil with the highest expression of PD-L1 in crypt epithelium, macrophages homing the germinal centers and interfollicular mononuclear leukocytes.
- Tumor tissues - prescreened for positive tumor and inflammatory infiltrates. PD-L1 expression varies by tumor type so screening is recommended to find positive and negative tumor controls.
- The following publication is useful for finding suitable tumor types for PD-L1 expression:
http://www.immunotherapyofcancer.org/content/1/S1/P53
- Note: Look for specimens with high numbers of inflammatory macrophages and mononuclear leukocytes.

Cell Lines:
- Positive controls: B-CPAP (high), ES-2 (medium), HCC70 (low).
- Negative controls: COLO205, see ab95356.

Primary antibody negative control: Recombinant Rabbit IgG isotype control antibody, ab172730.

Recombinant protein positive control: Recombinant human PD-L1 protein, ab167713.

RECOMMENDED PROTOCOLS
- For Western Blotting, Flow Cytometry and Immunohistochemistry, please refer to the PD-L1 RabMAb (clone 28-8) protocol booklet.

Immunohistochemistry usage:
For IHC usage on FFPE tissues, we recommend using PD-L1 IHC panel ab236676, which contains PD-L1 antibody clone 28-8 (ab205921), HIER antigen retrieval reagent (ab208572) and IHC detection kit HRP/DAB (ab209101).

Western blot usage:
For clone 28-8, it is recommended to use Odyssey system. This system has the advantages of a wider dynamic range and less background than chemiluminescence.

ALTERNATIVE VERSIONS
- Conjugated versions of this antibody are available (Alexa Fluor® 647, PE, HRP) here.
- A low endotoxin, azide free version of the antibody is available: ab209889.
- This PD-L1 antibody [28-8] has been used as detector antibody in Human PD-L1 SimpleStep ELISA® kit: ab214565.

This product is a recombinant monoclonal antibody, which offers several advantages including:

• - High batch-to-batch consistency and reproducibility
• - Improved sensitivity and specificity
• - Long-term security of supply
• - Animal-free production

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.